Trastuzumab emtansine

Cat. No.: HY-P9921

CAS No.: 1018448-65-1

Target: EGFR; Antibody-Drug Conjugates (ADCs)

Pathway: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Antibody-drug Conjugate/ADC Related

Storage: 4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Trastuzumab emtansine

BIOLOGICAL ACTIVITY

Description

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer[1][2].

In Vitro

Trastuzumab emtansine (2 μg/mL; 3 d) significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Trastuzumab emtansine (15 mg/kg; i.v. three to five times weekly for 3 weeks) exhibits significantly anti-tumor effect in mice [2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CB-17/SCID mice (6 weeks) were injected with OVA10 cells[2]
Dosage:	15 mg/kg
Administration:	I.v. three to five times weekly for 3 weeks
Result:	Showed remarkable inhibition of tumor growth in mice and was well tolerated.

CUSTOMER VALIDATION

- Adv Sci (Weinh). 2024 Jan 25:e2306309.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Verma S, et, al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783-91.

[2]. Menderes G, et, al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in

epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol. 2017 Oct;147(1):145-152.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA